Stanford Cancer Institute

Cancer Cell Therapy

Multiple Myeloma

Post-Auto

CCT5054
Phase II T Cell Therapy in MM w/Sub-Optimal Response After Autologous HCT & Maintenance Lenalidomide
Pi: Sidana
Sponsor: Pending

Relapsed

Patients with >= 3 prior lines of Therapy

CCT5075
Phase III bb2121 vs SoC Triplet Regimens in Relapsed & Refractory Multiple Myeloma (RRMM) (Kar/MMa-3)
Pi: Liedtke
Sponsor: Celgene Corporation
Priority 5

CCT5030
Phase I ALLO-715 Eval Anti-BCMA Allogeneic CAR T Cell Tx in Relapsed/Refractory Multiple Myeloma
Pi: Liedtke
Sponsor: Allogene Therapeutics
Priority 2

Patients with 1-3 prior lines of Therapy

CCT5057
Phase II ALLO-647 and ALLO-605, an Anti-BCMA, Allogeneic CAR TCell Therapy in Relapsed / Refractory Multiple Myeloma
Pi: Sidana
Sponsor: Allogene Therapeutics
Priority 1

CCT5060
Phase II Teclistamab Daratumumab Pomalidomide Dexamethasone Bortezomib in Relapsed / Refractory Multiple Myeloma
Pi: Sidana
Sponsor: Celgene Corporation

Auto

CCT5056
Expanded Access Protocol (EAP) in Idecabtagene Vicleucel that is Nonconforming for Commercial Release
Pi: Sidana
Sponsor: Celgene Corporation

CCT5059
Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out of Specification (OOS) for Commercial Release in Patients with Multiple Myeloma
Pi: Sidana
Sponsor: Janssen Scientific Affairs, LLC

CCT5063
A Phase III Randomized study Comparing VRd Followed by Ciltacabtagene Autoleucel Therapy Directed Against VRd followed by Rd Therapy in Newly Diagnosed Multiple Myeloma
Pi: Sidana
Sponsor: Janssen Scientific Affairs, LLC

KEY

- Pending
- Open for Enrollment
- Link
- Trial Posting
- Optional Path
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu